Delaying second Pfizer dose leaves cancer patients at risk, say researchers

Covid vaccination policy review urged after study finds 12-week gap leaves patients vulnerable

• Coronavirus - latest updates
• See all our coronavirus coverage

Delaying the second dose of the Pfizer/BioNTech vaccine must be urgently reviewed for cancer patients after a single shot was found to offer inadequate protection, researchers have said.

A study from King's College London and the Francis Crick Institute - which has not yet been peer reviewed - found that three weeks after the first jab antibody responses were found in 39% of people with solid cancers and 13% of people with blood cancer.